일동제약 — 공정거래자율준수프로그램운영현황(안내공시)  (20240802)
제출인: 일동제약

일동제약/공정거래 자율준수프로그램 운영현황(안내공시)/(2024.08.02)공정거래 자율준수프로그램 운영현황(안내공시)

공정거래 자율준수프로그램 운영현황(안내공시)

1. 제목
Compliance program operation performance in the first half of 2024 and fair trade voluntary compliance program operation plan for the second half of 2024

2. 주요내용
The company plans to disclose the status of the Compliance Program (CP).

Ⅰ. Performance of the Fair Trade Compliance Program Operation in the First Half of 2024

1. Strengthening the CP Operation System

1) Operation of the Anti-Corruption Management System (ABMS)

① Training for corruption risk and inspection evaluators

② Evaluation of corruption risk by department

③ Internal audits

2) Completion of the ISO 37001 (Anti-Corruption Management System) renewal audit(certification renewal)

3) Completion of the preparation of the expenditure report for economic benefits provided in 2023

4) Operation of a customer verification system for expenditure reports on economic benefits

2. CP Monitoring

1) CP monitoring

① Sanctions for violations of CP regulations: written warnings for 3 individuals

② Enhancement of on-site monitoring (same day, one night)

③ Pre- and post-monitoring of marketing and sales departments

2) Expenditure report on economic benefits

① Monthly monitoring and inspection of expenditure report preparation

② Selection and participation of companies in the pre-submission expenditure report survey

3. CP Education and Cultural Dissemination

1) Strengthening CP education

① Special training for new and experienced employees

② Group education in the ETC/CHC sector and regional CP education

③ ISO 37001 anti-corruption management system training

④ Implementation of a CP awareness survey for employees

⑤ Production and distribution of CP education videos

2) Cultural dissemination

① Conducting the voluntary compliance council under the pre-consultation system

② Ethical management workshop for the pharmaceutical industry (KPBMA) in the first half of 2024

③ Ethical management academy for the Pharmaceutical Industry (KPBMA and KRPIA) in the first half of 2024

④ Sharing and improving CP/ABMS operation status and post-audit results

Ⅱ. Fair Trade Voluntary Compliance Program Operation Plan for the Second Half of 2024

1. ISO 37001 management review reports to the Board of Directors (July 31, 2024)

2. The CEO's declaration of commitment to implement the compliance program

1) The CEO’s voluntary compliance message posted on the website

2) Voluntary compliance day ceremony in September 2024

① Signing of the compliance pledges by the entire employees

② Appointment of new departmental voluntary compliance officers

③ Awarding of CP compliance excellence teams and individuals (3 teams)

④ Engagement of external instructors for employee training

3. Strengthening CP Education and Cultural Dissemination

1) Strengthening CP education

① CP online education and testing for all employees

② ISO 37001 anti-corruption management system training

③ Group education for the ETC/CHC division and regional CP education

④ Refresher training for CP violators

⑤ CP education for new and experienced employees

⑥ Regular training in response to amendments to relevant laws and regulations

⑦ CP education for partners

2) Cultural dissemination

① Enhancement of rewards for departments and employees excelling in compliance with the compliance program

② Conducting a survey on employee CP awareness

4. Strengthening the CP Operation System

1) Revision of the CP strategy document

2) Enhancement of customer verification system for expenditure report details and monitoring of integrated management system

3) Pre- and post-monitoring of marketing and sales departments

4) Enhancement of on-site monitoring

5) Implementation of monitoring across all departments

3. 결정일자
2024-07-31

4. 기타 투자판단과 관련한 중요사항
-

※ 관련공시
-